Edwards Lifesciences Corp (EW)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $61.59B
Last updated: Nov 17, 2026 at 4:35 PM ET
Edwards Lifesciences Corp (EW) Statistics
Edwards Lifesciences (EW) has a market cap of $61.59B and an enterprise value of $59.16B. Its trailing P/E is 35.8x.
Total Valuation
Enterprise value is 3.95% below the market cap, as cash exceeds debt.
| Market Cap | $61.59B |
|---|---|
| Enterprise Value | $59.16B |
| Latest price (Nov 17, 2026) | $105.39 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 9.1x and 5.6x. Its year-end P/E ranged from 28.3x to 58.1x from 2016 to 2025.
| P/E Ratio | 35.8x |
|---|---|
| Forward P/E | 34.0x |
| P/S Ratio | 9.1x |
| Forward P/S | 9.0x |
| P/B Ratio | 5.6x |
| P/TBV Ratio | 7.8x |
| P/FCF Ratio | 42.6x |
| P/OCF Ratio | 35.9x |
| PEG Ratio | 3.0 |
Enterprise Valuation
Counting debt and cash, the company is valued at 41.0x EBITDA and 40.9x free cash flow.
| EV / Earnings | 58.3x |
|---|---|
| EV / Sales | 8.9x |
| EV / EBITDA | 41.0x |
| EV / FCF | 40.9x |
Price Statistics
The stock is up 22.12% over 52 weeks and trades 15.64% above its 50-day average.
| Beta (1Y) | 0.54 |
|---|---|
| 52-Week Change | +22.12% |
| 1-Month Change | +20.83% |
| 3-Month Change | +14.21% |
| 6-Month Change | +28.27% |
| 5-Year Change | -23.21% |
| 10-Year Change | +189.89% |
| Total Return (1Y) | +22.12% |
| Total Return (3Y CAGR) | +16.35% |
| Total Return (5Y CAGR) | -2.07% |
| Return vs SPY (1Y) | +13.85% |
| Max Drawdown (1Y) | -13.19% |
| Max Drawdown (3Y) | -37.53% |
| Sharpe Ratio (1Y) | 0.89 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $91.14 |
| 200-Day Average | $86.58 |
| 52-Week Range | $74.66 to $108.00 |
| RSI (14 Days) | 72.7 |
| Average Volume (20 Days) | 5.04M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 4.60x current liabilities, and total debt is 0.06x shareholder equity.
| Current Ratio | 4.60x |
|---|---|
| Quick Ratio | 3.86x |
| Debt / Equity | 0.06x |
| Debt / EBITDA | 0.48x |
| Debt / FCF | 0.48x |
| Interest Coverage | 55.12x |
Returns and Efficiency
Return on invested capital is 7.47% over the last 12 months, against a 5-year average of 8.47%.
| Return on Equity (ROE) | 9.34% |
|---|---|
| Return on Assets (ROA) | 7.17% |
| Return on Invested Capital (ROIC) | 7.47% |
| ROE (5Y Average) | 25.01% |
| ROA (5Y Average) | 18.14% |
| ROIC (5Y Average) | 8.47% |
| Asset Turnover | 0.49x |
| Inventory Turnover | 1.28x |
| Receivables Turnover | 7.05x |
| Cash Conversion Cycle | 286 days |
Taxes
Income tax took 31.05% of pretax income over the last 12 months.
| Income Tax (TTM) | $444.70M |
|---|---|
| Effective Tax Rate | 31.05% |
Scores
EW has an Altman Z-Score of 14.20, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 14.20 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $6.67B over the last 12 months is up 13.44% from the 12 months before.
| Revenue | $6.67B |
|---|---|
| Revenue Growth (YoY) | +13.44% |
| Gross Profit | $5.21B |
| Operating Income | $1.44B |
| Pretax Income | $1.43B |
| Net Income | $1.01B |
| Reported EPS (TTM) | $2.94 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 76.80% of the $14.14B in total assets.
| Cash and Equivalents | $3.11B |
|---|---|
| Total Debt | $679.60M |
| Net Cash | $2.43B |
| Net Cash Per Share | $4.22 |
| Working Capital | $5.67B |
| Shareholder Equity | $10.86B |
| Book Value Per Share | $18.85 |
| Tangible Book Value | $7.75B |
| Tangible Book Per Share | $13.44 |
| Total Assets | $14.14B |
| Total Liabilities | $3.18B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $292.80M of capital spending, operating cash flow left $1.42B of free cash flow.
| Operating Cash Flow | $1.72B |
|---|---|
| Capital Expenditures | $292.80M |
| Free Cash Flow | $1.42B |
| FCF Per Share | $2.47 |
| Depreciation and Amortization | $171.20M |
| Share Repurchases | $754.60M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 21.59%, against a 5-year average of 27.64%.
| Gross Margin | 78.02% |
|---|---|
| Operating Margin | 21.59% |
| Pretax Margin | 21.46% |
| Net Margin | 15.20% |
| FCF Margin | 21.34% |
| Gross Margin (5Y Average) | 79.57% |
| Operating Margin (5Y Average) | 27.64% |
| Net Margin (5Y Average) | 37.01% |
Growth
Revenue grew 10.77% a year over 3 years, and EPS 1.06% a year.
| Revenue Growth (3Y CAGR) | +10.77% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.70% |
| EPS Growth (3Y CAGR) | +1.06% |
| EPS Growth (5Y CAGR) | +6.71% |
| FCF Growth (3Y CAGR) | +11.10% |
| FCF Growth (5Y CAGR) | +15.58% |
| Operating Income Growth (3Y CAGR) | -5.51% |
| Book Value Per Share Growth (2Y CAGR) | +27.34% |
| Tangible Book Per Share Growth (2Y CAGR) | +23.30% |
Dividends and Yields
EW does not pay a dividend. Its free cash flow yield is 2.34%.
| Earnings Yield | 2.79% |
|---|---|
| FCF Yield | 2.34% |
| Buyback Yield | 0.93% |
| Shareholder Yield | 0.93% |
Stock Splits
The last split was a 3-for-1 forward split on Jun 1, 2020.
| Last Split Date | Jun 1, 2020 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 3:1 |
Peer Position
Against 11 similar companies, EW has the 2nd highest P/E.
P/E RatioPeer median 19.5x
P/S RatioPeer median 3.5x
ROICPeer median 8.43%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +8.50%
| P/E Ratio | 35.8x vs 19.5x median |
|---|---|
| P/S Ratio | 9.1x vs 3.5x median |
| ROIC | 7.46% vs 8.43% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +13.44% vs +8.50% median |
Analyst Forecast
Consensus estimates put revenue growth at 11.03% and EPS growth at 15.01% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +11.03% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +15.01% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About EW
What is EW's market cap?
Edwards Lifesciences has a market cap of $61.59B. Its enterprise value, which adds debt and subtracts cash, is $59.16B.
What is EW's P/E ratio?
Edwards Lifesciences has a trailing P/E ratio of 35.8x and a forward P/E of 34.0x.
How many shares of EW are outstanding?
Edwards Lifesciences has 576.30M shares outstanding. The count is down 1.44% from a year earlier.
Does EW pay a dividend?
No. Edwards Lifesciences does not pay a dividend.
How much debt does EW have?
Edwards Lifesciences has $679.60M of total debt and $3.11B of cash and equivalents, a net cash position of $2.43B.
EW pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts